EaveTubes for Vector Control (NCT05736679) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
EaveTubes for Vector Control
Côte d’Ivoire1,870 participantsStarted 2023-03-23
Plain-language summary
The goal of this clinical trial is to test whether In2Care EaveTubes (ETs) as a stand-alone tool can reduce malaria in an area where transmission is driven by insecticide-resistant Anopheles gambiae. Children who live in homes with ETs will be monitored for malaria infection and compared to children living in homes without ETs in Côte d'Ivoire where there is universal coverage of long lasting insecticide nets and pyrethroid resistance is high.
Who can participate
Age range
6 Months – 10 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Village Level Inclusion Criteria:
* ≥ 80% of Households (HHs) must be suitable for EaveTube(ET) installation.
* ≥70% of HHs willing to have ETs installed.
* No participation in the previous Screening + ETs cluster randomized control trial (cRCT).
* Received standard pyrethroid-only long lasting insecticide nets(LLINs) (Permanet 2.0).
* 100-300 HHs per village.
* ≥2 km apart from another village.
Village Level Exclusion Criteria:
* \< 80% of HHs suitable for ET installation.
* \<70% of HHs willing to have ETs installed.
* Villages being treated by indoor residual spray (IRS) and/or new generation bed net campaigns.
* Participation in previous Screening + ET cRCT.
* \<100 and \>300 households per village.
* \<2 km from another village.
Household Level Inclusion Criteria
* HHs must be suitable for ET installation.
* Provision of consent from heads of HH.
Household Level Exclusion Criteria
* HH not suitable for ET installation (e.g. houses with poor quality thatch roofing or very large eaves or wall gaps, houses in substantial disrepair, unfinished houses under construction, poorly constructed houses, ).
* No provision of consent from heads of HH.
Individual Level Inclusion Criteria
* Children aged ≥ 6 months to \< 8 years old at time of enrollment (so all participants are under 10 years old for the duration of clinical follow-up).
* Provision of written, informed consent by parents/care givers.
* Children must reside in villages enrolled in the study and in ETs-treated …
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.